Edwards Lifesciences Co. (NYSE:EW) VP Daniel J. Lippis Sells 330 Shares

Edwards Lifesciences Co. (NYSE:EW) VP Daniel J. Lippis sold 330 shares of the business’s stock in a transaction on Friday, May 9th. The shares were sold at an average price of $74.42, for a total transaction of $24,558.60. Following the transaction, the vice president now owns 26,616 shares in the company, valued at approximately $1,980,762.72. This represents a 1.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Edwards Lifesciences Trading Down 1.1 %

Shares of EW stock opened at $73.82 on Friday. The firm has a market capitalization of $43.40 billion, a P/E ratio of 10.59, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $95.25. The firm’s fifty day simple moving average is $71.48 and its 200 day simple moving average is $71.50. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The business had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.40 billion. During the same quarter in the prior year, the business earned $0.66 earnings per share. The firm’s revenue for the quarter was up 6.2% on a year-over-year basis. As a group, sell-side analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on EW shares. Royal Bank of Canada restated an “outperform” rating and issued a $85.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Robert W. Baird increased their price objective on Edwards Lifesciences from $72.00 to $75.00 and gave the stock a “neutral” rating in a report on Thursday, April 24th. Truist Financial cut their price objective on shares of Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating on the stock in a research report on Friday, April 11th. Canaccord Genuity Group increased their price target on shares of Edwards Lifesciences from $71.00 to $75.00 and gave the stock a “hold” rating in a research note on Friday, April 25th. Finally, Wolfe Research downgraded shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $79.45.

Institutional Trading of Edwards Lifesciences

Several institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Edwards Lifesciences by 10.4% in the 4th quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company’s stock worth $5,117,845,000 after buying an additional 6,537,494 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Edwards Lifesciences by 5.3% in the 4th quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company’s stock worth $2,458,601,000 after purchasing an additional 1,678,154 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Edwards Lifesciences by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 13,647,341 shares of the medical research company’s stock worth $1,007,520,000 after purchasing an additional 126,194 shares in the last quarter. Jennison Associates LLC lifted its holdings in Edwards Lifesciences by 34.3% during the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company’s stock valued at $731,036,000 after purchasing an additional 2,576,383 shares during the last quarter. Finally, Fisher Asset Management LLC grew its stake in Edwards Lifesciences by 7.7% during the fourth quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company’s stock worth $723,664,000 after buying an additional 696,965 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.